Unique ID issued by UMIN | UMIN000043407 |
---|---|
Receipt number | R000049561 |
Scientific Title | Effects of peptide ingestion on sleep: a randomized, double-blind, placebo-controlled, parallel-group study |
Date of disclosure of the study information | 2021/02/24 |
Last modified on | 2021/07/14 17:28:21 |
Effects of peptide ingestion on sleep: a randomized, double-blind, placebo-controlled, parallel-group study
Effects of peptide ingestion on sleep
Effects of peptide ingestion on sleep: a randomized, double-blind, placebo-controlled, parallel-group study
Effects of peptide ingestion on sleep
Japan |
No
Adult |
Others
NO
To evaluate the efficacy of peptide on sleep by comparing them to placebo
Efficacy
Evaluation of OSA Sleep Inventory MA version after 2 weeks of intake
Evaluation of the following items after 2 weeks of intake
1) questionnaires about stress and quality of life
2) salivary markers
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Intake of the peptide foods for 2 weeks
Intake of the placebo for 2 weeks
30 | years-old | <= |
65 | years-old | > |
Male and Female
1) Males and females aged 30-64 years old
2) Subjects who have received a full explanation of the study, understand its contents, and have given their written consent to participate in the study
1) Subjects who are undergoing medical treatment or diagnosed as needing medical treatment
2) Subjects who are pregnant, lactation, or planning to become pregnant during this study
3) Subjects who have history of serious disorders (Cerebrovascular disease, Cardiac disorder, Hepatic disorders, Gastrointestinal disorder, Endocrine-related disorder, etc.)
4) Subjects who have or have a history of sleep disorders such as insomnia or sleep apnea syndrome (SAS)
5) Subjects with medication allergies, food allergies, or a serious history of such allergies
6) Subjects who have or have a history of drug addiction or alcoholism
7) Subjects who are judged by the principal investigator to have an irregular lifestyle
8) Subjects who regularly use medicines, supplements, etc.
9) Subjects who urinate more than 3 times during the night
10) Extremely heavy drinkers (more than 60g/day of alcohol)
11) Subjects who have participated in other drug or food trials within the past month, or are willing to participate during this study
12) Subjects who are judged as ineligible to participate in this study by the principal investigator
70
1st name | Hatsuko |
Middle name | |
Last name | Abo |
KAYABA-CHO MENTAL HEALTH CARE CLINIC
director
103-0025
Nihonbashi Kayabacho2-8-10 Chuo-ku, Tokyo, Japan
03-5643-9855
phatsuko.ab@gmail.com
1st name | Shigeru |
Middle name | |
Last name | Imai |
Leverage Brain Inc.
Clinical Trial Department
105-0004
Shinbashi2-16-1 Minato-ku, Tokyo, Japan
080-7290-0404
imai@levbrain.com
Leverage Brain Inc.
Morinaga Milk Industry Co., Ltd.
Profit organization
Japan Conference of Clinical Research
1-13-23 Minamiikebukuro Toshima-ku, Tokyo, Japan
03-6868-7022
jccr-info@cts-smo.com
NO
茅場町こころのケアクリニック(東京都)
2021 | Year | 02 | Month | 24 | Day |
Unpublished
Completed
2021 | Year | 02 | Month | 18 | Day |
2021 | Year | 02 | Month | 18 | Day |
2021 | Year | 02 | Month | 24 | Day |
2021 | Year | 03 | Month | 31 | Day |
2021 | Year | 02 | Month | 22 | Day |
2021 | Year | 07 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049561
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |